EU accepts Astrazeneca's application for marketing gout treatment
22nd Jan 2015 07:59
The European medicine regulator has approved AstraZeneca's application to market its lesinurad 200mg tablets for gout. Lesinurad helps increase uric acid excretion from the body to relieve gout. The European Medicines Agency accepted the FTSE 100 drug developer's marketing authorisation application
Read moreFTSE 100 movers: BP boosted by lower-than-expected fine, ARM hit by Intel competition
16th Jan 2015 12:53
Oil giant BP was among the risers after the company revealed it faces a maximum penalty of $13.7bn under the Clean Water Act. This follows the District Court for the Eastern District of Louisiana ruling on the Deepwater Horizon case, which found that 3.19m barrels of oil were discharged in the Gulf
Read moreAstraZeneca hails success in Brilinta cardiovascular trial
14th Jan 2015 08:02
A large-scale clinical trial of AstraZeneca's Brilinta tablets for patients with a history of heart attack has been successful in proving its effectiveness, the drug developer said. The Pegasus-TIM 54 study, which involved over 21,000 patients, "successfully met its primary efficacy endpoint", with
Read moreBroker tips: AstraZeneca, Laird, Housing stocks, Oil prices
9th Jan 2015 11:43
AstraZeneca's drug pipeline is still "under-appreciated", according to UBS which hiked its target price for the stock by 10% on Friday. The bank said it sees a number of "blockbuster opportunities" for the pharmaceutical group in the near term, as it lifted its target for the shares from 5,000p to 5
Read moreUBS hails pipeline potential at AstraZeneca, lifts target price by 10%
9th Jan 2015 10:52
AstraZeneca's (AZN) drug pipeline is still "under-appreciated", according to UBS which hiked its target price for the stock by 10% on Friday. The bank said it sees a number of "blockbuster opportunities" for the pharmaceutical group in the near term, as it lifted its target for the shares from 5,000
Read moreLondon midday: Resource stocks drag FTSE 100 into the red
5th Jan 2015 11:36
UK stocks were trading firmly in the red by Monday lunchtime despite a positive start, with shares in the oil and mining sectors providing a drag. London's FTSE 100 was down 0.9% at 6,489 by midday, dropping sharply after reaching a high of 6,576.74 early on. This week will be the first full tradin
Read moreLondon open: UK stocks rise ahead of data-heavy week, M&S falls
5th Jan 2015 08:18
After an initial dip, UK stocks pushed into positive territory early on Monday as traders returned to their desks after the festive holidays in an optimistic mood. London's FTSE 100 index was up 0.4% at 6,571, quickly bouncing off an intraday low of 6,522.59 reached shortly after the open. "This Mo
Read moreSector movers: Defensive pharma stocks fall as Santa Rally continues
23rd Dec 2014 16:18
Pharmaceutical and healthcare stocks were leading the fallers on Tuesday as investors dumped defensive assets amid a continued pre-Christmas rally. UK stocks have risen for six straight days as markets rebounded strongly following a recent sell-off. While more cyclical sectors such as construction
Read moreLondon pre-open: Stocks to soar after Federal Reserve statement
18th Dec 2014 07:33
UK stocks were set to surge when markets open on Thursday morning following massive gains on Wall Street as investors reacted to comments from the Federal Reserve. City sources predict the FTSE 100 will open around 110 points higher than Wednesday's close of 6,336.48. US markets jumped late on with
Read moreAstrazeneca's Lynparza capsules given green light from European Commission
18th Dec 2014 07:09
British pharmaceutical giant AstraZeneca has received marketing authorisation from the European Commission for its Lynparza cancer treatment. The firm said the capsules will be used to treat adult patients suffering from epithelial ovarian, fallopian tube, or primary peritoneal cancer who respond fu
Read moreLondon pre-open: FTSE to fall early on amid Fed speculation, Tesco in focus
9th Dec 2014 07:44
Stocks are expected to suffer a drop early on in Tuesday's session following suggestions the Federal Reserve could next week withdraw its commitment to low interest rates. City sources predict the FTSE 100 will open around 40 points lower than Monday's close of 6,672.15. "For a long time, the Fed h
Read moreAstrazeneca granted approval for opioid-induced constipation treatment
9th Dec 2014 07:05
Astrazeneca announced that, Moventig, its treatment for adults with opioid-induced constipation (OIC), has been granted marketing authorisation by the European Commission for patients who have had an inadequate response to laxatives. The drug is the first of its kind to be approved in the European U
Read moreWednesday broker round-up
3rd Dec 2014 09:41
AstraZeneca: Morgan Stanley increases target price from 4100p to 4300p, while downgrading to 'underweight'. BG Group: Barclays reduces target price from 1300p to 1100p and reiterates an 'equal-weight' rating. Credit Suisse reduces target price from 1050p to 940p and maintains an 'underperform' ratin
Read moreLondon pre-open: Stocks to gain ahead of quiet session
2nd Dec 2014 07:40
London-listed stocks are expected to begin Tuesday's session on a positive note ahead of what is expected to be a fairly quiet day. City sources predict the FTSE 100 will open around 19 points higher than Monday's close of 6,656.37. The session will see the release of the Markit/CIPS construction r
Read moreAstrazeneca's application for lung cancer treatment accepted by FDA
2nd Dec 2014 07:11
Astrazeneca said the US Food and Drug Administration (FDA) has accepted its new drug application for Iressa, a treatment designed for use in with a particular kind of lung cancer. It is already approved in 90 countries, having first been launched in 2002. Iressa acts by blocking the transmission of
Read more